Test Price
2,800 AED✅ Home Collection Available
DPYS Gene Dihydropyrimidinuria Genetic Test in UAE | 2800 AED | DHA Guidelines
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The DPYS Gene Dihydropyrimidinuria Genetic Test detects pathogenic variants in the DPYS gene responsible for dihydropyrimidinuria, a rare autosomal recessive disorder of pyrimidine catabolism. This test empowers timely diagnosis, family screening, and personalized management for patients suspected of metabolic disturbances.
| Feature | Our Test (NGS) | Closest Alternative (Single-Gene Sequencing) |
|---|---|---|
| Technology | Next-Generation Sequencing (NGS) with full gene coverage | Sanger sequencing limited to select exons |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Detection Rate | >99% for known pathogenic variants | ~85% (misses deep intronic/CNV) |
Physician Insight & Safety Protocols
“This test provides rare insight into an often overlooked metabolic pathway. Yet, no genetic result stands alone—please integrate findings with your clinical examination and metabolic workup. We are here to support a nuanced interpretation that truly serves your health journey.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Safety Advisory
Do not discontinue any prescribed medication without consulting your doctor. This test does not replace a full clinical evaluation. Any changes to therapy should be made only under the supervision of your healthcare provider.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Minors without legal guardian consent (as per UAE Federal Law No. 2 of 2019 and PDPL provisions); patients unable to provide a valid sample; individuals lacking clinical or family-history-based suspicion of dihydropyrimidinuria.
- Emergency Red Flags: Sudden onset of seizures, unexplained lethargy, vomiting, or respiratory distress in an infant—seek immediate emergency care; do not wait for test results.
Patient FAQ & Clinical Guidance
1. What exactly does the DPYS Gene Dihydropyrimidinuria test detect?
This advanced DNA test analyzes the DPYS gene for mutations causing dihydropyrimidinuria, a rare metabolic disorder affecting pyrimidine breakdown. It identifies single nucleotide variants, small insertions/deletions, and copy number changes that impair dihydropyrimidinase enzyme function. Results guide diagnosis, carrier status, and therapeutic strategies.
2. How is the sample collected and what can be used?
A blood sample, extracted DNA, or a single drop on an FTA card is acceptable for testing. Our VIP Mobile Phlebotomy team will handle venipuncture or capillary blood spotting, ensuring cold-chain integrity until the sample reaches our ISO-certified laboratory. Home collection is available daily from 8 AM to 11 PM.
3. How long do results take and how will I receive them?
Results are typically available within 3 to 4 weeks, reported securely through our encrypted patient portal. You will also receive a telephonic interpretation session with a clinical genetic counselor to clarify the implications and next steps.
UAE Regulatory & Data Privacy Adherence
This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted and handled with strict confidentiality. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | DPYS Gene Dihydropyrimidinuria Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Blood, Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage including intronic and CNV detection |
| ICD-10-CM Code | E79.8 |
| LOINC Code | 21639-8 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians